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Tumor blood vessels express specific
markers that are not present in the blood
vessels of normal tissues (Ruoslahti,
2002). Such marker molecules can be
present in the endothelium, the peri-
cytes, or the extracellular matrix of tumor
blood vessels. Lymphatic vessels in
tumors can also be distinct from those in
normal tissues (Laakkonen et al., 2002).
Many of the marker molecules that are
selectively expressed in tumor blood
vessels are proteins associated with
tumor-induced angiogenesis, the sprout-
ing of new blood vessels (Ruoslahti,
2002). These proteins are often function-
ally important in the angiogenesis
process, and agents that perturb their
function can be used to suppress angio-
genesis. In a recent paper, Hood et al.
(2002) put an angiogenesis marker pro-
tein, the αvβ3 integrin, to a different use
as a target for concentrating a gene ther-
apy vector at tumor vessels (Figure 1).
Previous work, mostly from the same
laboratory, has shown that the αvβ3 inte-
grin is selectively expressed in angio-
genic vessels, and that antibodies and
peptides capable of blocking its activity
are antiangiogenic. Nanoparticles con-
taining a contrast agent, an anti-αvβ3
antibody (Sipkins et al., 1998), and bac-
teriophage displaying an αvβ3 binding
RGD peptide (Arap et al., 1998) become
concentrated in tumor vessels after a
systemic injection. Cheresh and col-
leagues have combined these elements
with a dominant-negative Raf-1 gene to
assemble a novel vector for gene therapy
of tumors in mice. The design is innova-
tive and the first treatment results are
impressive.
Delivering the nanoparticles to the
αvβ3 integrin made it possible to achieve
10- to 15-fold tumor targeting selectivity
relative to untargeted particles. More-
over, by growing the tumors using a cell
line that does not express the integrin,
they could restrict the delivery to the
blood vessels (and possibly other stro-
mal elements) in the tumor. The αvβ3
integrin is selectively expressed in angio-
genic vessels, and little expression is
seen in resting blood vessels. These and
previous results by Arap et al. (1998)
show that delivering therapeutic agents
to αvβ3 in mouse tumors, including
metastases in the lungs and liver, can
produce impressive results. However, it
remains to be seen how universal these
results are, and in particular, how exten-
sively αvβ3 is expressed in the vascula-
ture of human tumors. It would also be
interesting to know whether the endothe-
lial precursor cells that migrate from the
bone marrow to sites of angiogenesis
(Grant et al., 2002) express αvβ3. If so,
an αvβ3-based therapy might intercept
these cells even before they reach the
angiogenic site.
The temporal and spatial expression
profiles of other potential target mole-
cules in tumor vasculature may differ
from those of αvβ3, potentially broaden-
ing the possibilities for drug delivery.
Another way of ensuring a broad effect
on tumor vessels might be to deliver the
therapeutic agent not only to an
endothelial target, but to make use of
specific target molecules on the peri-
cytes and extracellular matrix of tumor
blood vessels.
The nanoparticles used as a target-
ing vehicle in this study are bifunctional-
ized, crosslinked lipid micelles that carry
on their surface an αvβ3 binding com-
pound and a cationic lipid that binds
DNA. Any particle injected into the blood-
stream tends to be taken up by the retic-
uloendothelial system (RES). Various
treatments, such as coating with polyeth-
ylene glycol, are often needed to reduce
the RES uptake of particles. The
nanoparticles used by David Cheresh’s
group delivered remarkably little gene
activity to the liver, which is the main
RES site. The authors only measured
gene activity in the liver, so it is possible
that the particles were lodged in the liver
but that the expression vector DNA was
not transduced or was for some other
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A mutant Raf-1 gene loaded onto nanoparticles, delivered to tumor vasculature with an integrin binding compound, pro-
vides effective antiangiogenic gene therapy in mice.
Figure 1. Nanoparticles specifically target
tumor vasculature
Circulating nanoparticles bind to integrin on
the endothelial cells of tumor vessels, but do
not bind to the vessels in normal tissue. The
bound particles discharge their DNA cargo
into the cells. Thanks to Dr. Masanobu
Komatsu for preparing the illustration.
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reason not expressed. While the effects
on normal tissues require further study,
the vehicle clearly produced the desired
differential gene expression in the tumor.
The specificity of the treatment
effects achieved in this study is likely to
be a net effect of three factors: accumu-
lation of the vehicle at the tumor vascula-
ture, selective transduction of the pay-
load DNA into the αvβ3-expressing cells,
and possibly, selective susceptibility of
the proliferating endothelial cells in
angiogenic vessels to inhibition of the
Raf-1 pathway. Future gene therapies for
cancer are likely to use such combina-
tions of selective effects. Targeting will
increase effectiveness and reduce the
likelihood of side effects, as will the
selectivity of the targeted gene.
The treatment devised by Cheresh
and collaborators was very effective as
they were able to achieve tumor regres-
sion in mice, and some of the mice sur-
vived prolonged periods of time with no
gross evidence of tumors after a single
injection of the targeted nanoparticles.
One would expect antiangiogenics to be
able to prevent further growth of a tumor,
but not to affect the existing parts of the
tumor where the established blood ves-
sels should not be affected. The tumor
used in this study grew fast and maximal
tumor burden was reached in less than 3
weeks. Most of the blood vessels in
these fast-growing tumors would be
“new” and likely to carry angiogenesis
markers such as the αvβ3 integrin, which
could make these tumors particularly
responsive to antiangiogenic therapy. As
human tumors grow over years, a
greater proportion of their vessels may
be more mature and less susceptible to
antiangiogenics than fast-growing exper-
imental tumors.
Destroying established tumor vessels
is likely to require a combination of antian-
giogenic and antivascular therapy. As
blood vessels mature, they acquire a peri-
cyte coating and associated extracellular
matrix. Tumor-specific changes in these
vascular elements, such as the NG2 pro-
teoglycan in pericytes (Ozerdem et al.,
2001) and oncofetal fibronectin in the
matrix (Xu et al., 2001; Halin et al.,
2002), may make it possible to develop
targeted delivery approaches for antivas-
cular therapy. If sufficient damage to the
vessels is achieved, thrombosis of the
affected vessels may be initiated, provid-
ing a natural amplification mechanism for
the treatment (Huang et al., 1997).
Tumor blood vessels may also have
specific markers, the expression of which
is not regulated by angiogenesis. In vari-
ous normal tissues, the blood vessels
carry tissue-specific markers (Ruoslahti,
2002). In analogy with this, tumors may
put a signature on their vasculature.
Discovery of such marker molecules in
tumor blood vessels would further
expand the vascular targeting possibili-
ties, as may targeting through the lym-
phatic vessels (Laakkonen et al., 2002).
The future of antivascular tumor thera-
pies is likely to be similar to current
tumor treatments, which rely on combi-
nations of drugs; the most effective
approach may be a concerted attack at
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